Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Sezary Syndrome 1Mycosis Fungoides 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia 1Kidney Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Renal Cell 1

Interventions

Alemtuzumab 2ruxolitinib 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1Interleukin-15 1Daclizumab 1Cyclophosphamide 1B3(Fv)-PE38KDEL recombinant immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia-Lymphoma, Adult T-Cell × denileukin diftitox × Clear all
NCT00117845 2019-11-19

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
17 enrolled 9 charts
LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡